Abstract 725
Background
FAT1 gene is localized on chromosome 4q35.2 coding a 506KDa transmembrane protein and functions as an oncogene or tumor suppressor depending on tissue types in human cancers. Our lab has identified that FAT1 has oncogenic role in glioblastoma (GBM). PDCD10 gene encodes an evolutionarily conserved protein that is widely expressed in almost all human tissues. Here in our study we are characterizing the role of FAT1 gene in primary brain tumors and in the regulation of miRNAs and its target gene in GBM.
Methods
In order to delineate molecular crosstalk among factors driving glioma progression, we used knockdown method in glioma cell lines followed by expression analysis by Q-PCR. FAT1 knockdown was done using FAT1 specific siRNA and mRNA and miRNA expression analysis by specific primers in GBM cell lines. Expression and Spearman correlation analysis of FAT1 with miR-221-3p and PDCD10 was done in GBM tumor samples (n = 30). In a sequential bioinformatics study, we analyzed TCGA GBM dataset for FAT1 and PDCD10 expression and perform spearman correlation in GBM tumors (n = 430) as compared to normal brain (n = 10).
Results
On FAT1 knockdown, using FAT1 specific siRNA we observed significantly decreased expression of miR-221/222-3p. In-silico analysis recognized, PDCD10 as a potential targets of miR-221/222-3p. Furthermore, FAT1 knocked-down cells showed significantly increased expression of PDCD10 in all studied glioma cell lines. In order to validate our in-vitro observation and its clinical relevance, we have done expression and correlation study in GBM tumor samples. We observed significant positive spearman correlation between FAT1 and miR-221-3p (r = 0.5669, p ≤ 0.0011) and negative correlation of FAT1 with PDCD10 (r= -0.3492, p ≤ 0.0585),) and miR-221-3p with PDCD10 (r = 0.526, p ≤ 0.0028). In TCGA database we have observed negative correlation between FAT1 and PDCD10(r= -0.4209, p ≤ 0.0001). These results propose that FAT1 regulating the expression of miR-221-3p leading to downregulation of PDCD10 in GBM cell lines and GBM tumors.
Conclusions
Our in-vitro and GBM tumor data for the first time suggesting FAT1 to be a novel molecule regulating the expression of PDCD10 via miR221-3p in GBM.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
DST.
Funding
AIIMS.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
750 - HER2 positive rates in Invasive Lobular Breast Carcinoma : A study amongst 1,095 consecutive Asian patients
Presenter: Ga Jing Kee
Session: Poster display - Cocktail
Resources:
Abstract
1417 - CanAssist-breast -an immunohistochemistry based test for risk of recurrence prediction for early stage breast cancer patients: a cost-effective and accurate solution for Asia
Presenter: Manjiri Bakre
Session: Poster display - Cocktail
Resources:
Abstract
1468 - Topical silymarin administration for prevention of radiodermatitis in breast cancer patients: a randomized, double-blind, placebo-controlled clinical trial
Presenter: Sepideh Elyasi
Session: Poster display - Cocktail
Resources:
Abstract
873 - Comparison of interstitial brachytherapy with volumetric modulated arc therapy for tumour bed boost following breast conservative surgery
Presenter: Kannan Periasamy
Session: Poster display - Cocktail
Resources:
Abstract
1140 - Triple Negative Breast Cancer and Platinum-based Systemic Treatment: Meta-analysis and Systematic Review
Presenter: Jessa Gilda Pandy
Session: Poster display - Cocktail
Resources:
Abstract
168 - Longitudinal study on incidences of obesity and weight changes in Chinese patients with early-stage breast cancer
Presenter: Winnie Yeo
Session: Poster display - Cocktail
Resources:
Abstract
311 - Effect of combined CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome in breast cancer indicates endogenous and exogenous interplay
Presenter: Hanjing Xie
Session: Poster display - Cocktail
Resources:
Abstract
669 - A novel nipple aleolar complex involvement predictive index (NACPI) for indicating nipple sparing mastectomy in breast cancer
Presenter: Hirohito Seki
Session: Poster display - Cocktail
Resources:
Abstract
938 - Multicenter Trial for Safety and Toxicity of Nanoxel®M in Breast Cancer
Presenter: Tae Hyun Kim
Session: Poster display - Cocktail
Resources:
Abstract
1129 - Implication of PET-CT to improve negative predictive value for axillary lymph node metastasis in early breast cancer
Presenter: Oyeon Cho
Session: Poster display - Cocktail
Resources:
Abstract